Under-the-skin Sarclisa found as effective as approved formulation
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab)…
Myeloma
Latest news
Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a…
Cell therapy anito-cel shows promise for hard-to-treat RRMM
Most people with relapsed or refractory multiple myeloma…
